Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HoodiadexL10 is a dietary supplement marketed primarily for weight management and appetite suppression. It is derived from the *Hoodia gordonii* plant, a succulent indigenous to the Kalahari Desert in Southern Africa. The primary active constituent is a steroidal glycoside designated as P57. The purported mechanism of action involves the modulation of the hypothalamus, where P57 is believed to increase the content of adenosine triphosphate (ATP), thereby mimicking the physiological signal of high blood glucose levels and inducing a state of satiety in the central nervous system. This process results in a reduction of hunger and subsequent caloric intake. HoodiadexL10 is categorized as a nutraceutical and was widely popularized during the mid-2000s as a natural weight-loss aid, although clinical evidence regarding its long-term safety and efficacy in humans remains limited.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HoodiadexL10.